Table 1.
Patient characteristics by dose category of prednisone.
| Group 1 (≤10mg) n=64 |
Group 2 11–20mg n=57 |
Group 3 (≥21mg) n=28 |
Group 4 Non-responders n=15 |
|
|---|---|---|---|---|
| Median Minimally Effective Dose of Prednisone in mg (range) |
5 (1.5–10) |
16 (11–20) |
37.5 (21–80) |
NA |
| Gender M/F |
38M/26F | 26M/31F | 10M/18F | 5M/10F |
| Race W/B/A/O/U* |
55/4/4/0/1 | 53/2/2/0/0 | 22/5/1/0/0 | 11/3/1/0/0 |
| Median peak AEC (range) |
4164 (500–48080) |
7900 (910–76500) |
4824 (897–26688) |
11237 (1100–82000) |
| Median Age in years (range) |
52.5 (2–85) |
42 (4–84) |
42 (14–63) |
49 (16–70) |
| Median Serum IgE level in unit (range) |
164.5 (3.3–6530) | 277 (5–16300) | 214 (3.7–42874) | 93.2 (1.6–2786) |
| Median Serum B12 level in (range) |
603.5 (227–3914) |
664 (293–5055) |
677 (201–1312) |
993 (205–2583) |
| Median Serum Tryptase level in (range) |
5.32 (0.99–18.4) |
4.86 (0.99-28.1) |
5.20 (1.22–16.5) |
4.5 (1.7–25.3) |
| Median Serum LDH in (range) |
193 (115–409) |
203 (90–435) |
205 (115–695) |
313 (100–587) |
| HES Subtype | ||||
| I-HES | 38 | 26 | 15 | 6 |
| HES/EGPA | 15 | 18 | 5 | 0 |
| LHES | 5 | 8 | 8 | 3 |
| MHES | 0 | 0 | 0 | 5 |
| SO-HES | 6 | 5 | 0 | 1 |
| Organ involvement | ||||
| Cardiac | 9/64 (14%) | 5/57 (9%) | 4/28 (14%) | 9/15 (50%) |
| Neurologic | 12/64 (19%) | 14/57 (25%) | 9/28 (32%) | 4/15 (27%) |
| Pulmonary | 37/64 (58%) | 39/57 (68%) | 17/28 (61%) | 10/15 (67%) |
| Gastrointestinal | 22/64 (34%) | 19/57 (33%) | 12/28 (43%) | 5/15 (33%) |
| Dermatologic | 32/64 (50%) | 36/57 (63%) | 20/28 (71%) | 9/15 (60%) |
| Sinus | 24/64 (37.5%) | 31/57 (54%) | 16/28 (57%) | 4/15 (27%) |
*
W-White, B-Black or African-American, A-Asian, O-Other, U-Unknown.
Abbreviations: LDH-Lactose dehydrogenase, IHES-idiopathic hypereosinophilic syndrome; HES/EGPA-Hypereosinophilic syndrome/Eosinophilic granulomatosis with polyangiitis; LHES-lymphocytic variant hypereosinophilic syndrome, MHES-myeloid hypereosinophilic syndrome, SO-HES-single organ hypereosinophilic syndrome.